bioAffinity Technologies, Inc. — Form S-1
Filed November 20, 2026 · analyzed by the Registration Agent
S-1
— Neutral
significance 28/100
What the filing says
bioAffinity Technologies filed an S-1 registration statement on November 20, 2026, to permit selling stockholders to resell up to 999,673 shares of common stock, comprised of 980,072 shares issuable from Series C warrants (exercise price $6.122/share) held by Armistice Capital Master Fund Ltd., and 19,601 shares from Placement Agent Warrants (also $6.122/share). The company receives no proceeds from share sales but may receive ~$6.1 million if all warrants are exercised for cash. No company capital is raised by this registration.
Why this rating
Warrant-exercise registration is routine for small-cap biotech. While potential $6.1M inflow is 27% of $22.6M market cap, receipt is contingent and optional. No immediate capital or strategic change occurs.
See more from November 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.